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Abstract. Currently, Indonesia is in the 5 th rank of the highest tuberculosis prevalence over the world. The treatment of 
tuberculosis is going complicated due to the side effect experienced by the patients. The four combination of 
antituberculosis agent used in minimally 6 months of treatment could stimulate the hepatotoxicity as the one of the 
dominant side effect in tuberculosis treatment. Thus, it is important to do the Therapeutic Drug Monitoring (TDM) to 
optimize the tuberculosis treatment. This study is aimed to validate the TDM of pyrazinamide in human plasma using 
High Performance Liquid Chromatography-UV. We recruited 6 TB patients in the validation of pyrazinamide study. The 
C18 column shim- pack VP-ODS (250 mm x 4.6 mm, id 5μm) and aquabidest-acetonitrile as mobile phase were applied 
in this study. We used Shimadzu HPLC system with a model AT LC20 LC 10AT pump, detector SPD 20A and LC 
solution software. We performed the analysis for linearity, system appropriateness, accuracy and recovery to develop the 
validation method. This study has been approved by National Ethics Committee of Health Research. Our study shows 
that the linearity is good with value of r2> 0.99 and the equation y = 16740.876x - 2953.615.  The CV TR and CV peak 
area for system suitability are 1.46% and 0.29%, respectively. The LoD and LoQ value are 2.532 and 7.672 μg/mL , 
respectively. The accuracy on the concentration of 1.00, 8.00, 60.00 ug/ml are 108.80 %, 92.57 % and 100.98 %, 
respectively for intraday accuracy and 103.18 %, 92.44%, and 94.94%, respectively for interday accuracy.  Furthermore, 
the precision on the concentration of 1.00, 8.00, 60.00 ug/ml are 1.17%, 3.57%, 3.32%, respectively for intraday 
precision and 3.66%, 1.37% and 1.59%, respectively for interday precision. In conclusion, the method which we applied 
in this study was sensitive and reliable for routine TDM of pyrazinamide. 
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BACKGROUND 
Tuberculosis is still being one of communicable diseases which can cause of death. In 2013, around 9.0 million 
people were still experiencing tuberculosis and 1.5 million people died due to it. The rapid diagnosis and effective 
treatment could decrease the mortality and prevalence of tuberculosis  [1]. In developed country, even though the 
government has adopted the Direct Observed Treatment Shortcourses (DOTS) from WHO, the burden of 
tuberculosis is still high [1]. 
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Isoniazid, Rifampicin, Ethambutol and Pyrazinamide are four anti-tuberculosis agents which should be used as 
first line treatment of tuberculosis for minimally 6 month duration of treatment. These combination may cause drug 
interaction and adverse drug reaction.  
Pirazinamide is derivative of nicotinic acid which has similar structure with isoniazid. It well absorbed orally and 
widely distributed throught the body. Its mechanism as anti-tuberculosis is bactericidal and sterilizers working in 
acid medium, like machrophages and sites of acute inflammation. Pyrazinamidase is an enzyme which converts 
pyrazinamide into pyrazinoic acid. Pyrazinoic acid can decrease the intracellular pH which finally inactivated some 
enzymes [2,3].  
Previous study about pharmacokinetic parameters of first-line antituberculosis showed that the treatment failure 
was depend on the pharmacokinetic parameters. The decrease of AUC of pyrazinamide, isoniazid and rifampicin 
may cause the poor long-term outcome [4].  Long duration of tuberculosis treatment may cause side effect. The most 
side effect experience by patients and were responsible on the poor adherence of tuberculosis treatment were 
hepatitis, dyspepsia, exanthema and athralgia. The major side effects of pyrazinamide are exanthema, hepatotoxicity 
and gastrointestinal disturbances. Thus, to increase patients’ adherence during the tuberculosis treatment, the side 
effect monitoring should be closely done. Furthermore, patients should be well informed about these side effect and 
the medication to overcome the side effect.However, due to the complex treatment of tuberculosis, such as the 
potential of drug interaction and averse drug effect, the  Therapeutic Drug Monitoring (TDM) can be done as one 
method to optimize the therapeutic effect and to minimize the adverse effect [5]. TDM also can be applied to define 
the slow response of patients and the resistance to the antituberculosis  drugs. Thus, it is important to develop the 
TDM method in the country with high burden of tuberculosis disease. This study is aimed to validate the TDM of 
pyrazinamide in human plasma using HPLC-UV.  
 
METHOD 
Subjects 
We recruited six adult tuberculosis patients of Public HealthCenter in Yogyakarta. The blood sample was drown 
from cubiti venous as much as 5 mL 2 hours after the patients taking the antituberculosis drug. We gave the 
informed consent to the patients and asked them to signature the informed consent form as the participants. This 
research has been aproved by National Ethic Commitee of Health Research. 
Reagents  
This research used HPLC Shimadzu LC20 AT with LC 10AT pump, SPD 20A detector and LC solution 
software. The column C18 shim-pack VP-ODS (250 mm x 4.6 mm, id 5 μm) was used in this instruments with other 
glass instruments (IWAKI pyrex). 
The chemiclas used were from Merck (Germany), such as; methanol pro analysis (pa, 3906609839), diethyl ether 
(pa), 10% of trichlor acetic acid (TCA), acetonitryl (pa, 1632730213) and aquabidest. The pyrazinamide as standar 
compund was from BP/USP/COS.DIFC CO., LTD, Korea.  
Sample Preparation 
The standard curve was defined using 450 μL of plasma added by 50 μL pyrazinamide solution with 
concentration of 10.0; 80.0 and 600.0 μg/mL. The concentration of standard curve for linearity  were 1.0; 2.0; 4.0; 
8.0; 16.0; 30.0; and 60.0 μg/mL. The concentration of standard curve for accuracy, intraday precision and interday 
precision were 1.0; 8.0 and 60.0 μg/mL.  The 1000 μL of TCA 10% was added into the solution then followed the 
next procedures; 20 minutes of vortex with maximal speed, 10 minutes of centrifuge with 13000 rpm and 4oC of 
temperature. The 3 mL of ether was added into the supernatan for extraction process. This technique was aimed to 
separate pyrazinamide from other medications. The 20 mL of water solution of extraction process was injected into 
HPLC [6,7] 
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System Suitability Test.  
The system suitability was defined by injected the 20 μL of one point of standard  curve into HPLC system. This 
procedures were replicated for 6 times and the coefficient of variance was defined from retention time and wide of 
area ratio [8,9]. 
Linearity. 
The Area Under the Curve (AUC) of pyrazinamide was assesed to get the linear regression equation; y=bx+a 
with R>0.99. The AUC showed the association between ration of pyrazinamide concentration and area wide or the 
high of peak of chromatography [8,9]. 
Limit of Detection (LoD) and Limit of Quantification (LoQ).  
The value of  LoD and LoQ were define using the linear regression equation and Standard of Deviation (SD). 
The ration of signal to noise (S/N) with comparison of 3;1 was defined as LoD and the 10:1 comparison of S/N was 
defined as LoQ [8,9]. 
Accuracy 
The accuracy was examined from recovery. The value of recovery (%) was computed from  actual concentration 
of pyrazinamide divided by theoritical concentration of pyrazinamide and was counted in %. The criterion met 
accuracy with acceptance criteria required by USFDA  was 80-120% [8,9].  
Intraday and Interday precision 
The precision intraday could be seen from coefficient of variation (CV,%) of each replication of standard curve. 
The required CV for precision is less than 15%  [8,9]. 
Instrumental parameters 
HPLC : Shimadzu 
Stationary phase : Shim-pack VP-ODS (C18) 250 
x 4,6 mm Column 
Mobile phase : Aquabidest : Acetonitrile 
(97:3)% 
Flow rate : 1 mL/minute 
Detector  : UV 262 nm 
Retention time : 15 minute 
Injected volume : 20 μL 
 
RESULTS 
Our study defined that the method used in the validation procedures of pyrazinamide can be applied in clinical 
setting. Table 1 shows the results of system suitability test, linearity, LoD and LoQ. All the parameters met the 
requirement for validation test.  
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TABLE 1. System suitability test, Linearity, LoD and LoQ of Pyrazinamide using HPLC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The graph 1 presents the regression analysis results in system suitability test.  System suitability was 
performed to determine the effectivity of system when the method was applied. The results of system suitability 
were met the required criteria which was less than 2%. The linearity was shown in graph 1 with the R= 0.999 and 
the equation was y=16740,876x+2953.615.  
 
 
 
GRAPH 1. Linier regression between pyrazinamide concentration and AUC 
 
 
The value of LoD and LoQ were established to understand the lowest concentration of sample which had good 
accuracy and precision. Both of the LoD and LoQ had the value less than 3:1 and 10:1, respectively.  
The precision and accuracy results are liste in Table 2. The intraay and interday accuracy and precision were met 
the required criterion which are CV < 15% and value between 80-120%, respectively. Table 2 shows the precision 
and accuracy of TDM method of pyrazinamide in HPLC. 
 
 
 
 
 
 
 
Parameter Required Criteria* Results 
System Suitability CV ≤ 2% CV TR = 1,46% 
CV peak area = 0,28% 
Linearity  r ≥ 0,99 r = 0,999  y = 16740.876x - 2953.615 
LoD S/N ≈ 3:1 2,532 μg/mL 
LoQ S/N ≈ 10:1 7,672 μg/mL 
CV = Coefficient of Variation; TR = Retention Time; r = coefficient of correlation; LOD =  Limit of Detection; LOQ 
=Limit of Quantification 
* Adopted from [8]; [9]  
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TABLE 2. Precision and Accuracy of Pyrazinamide TDM using HPLC 
 
*: US FDA acceptance criteria for accuracy and precision 
DISCUSSION 
 
In general, we present that the method for pyrazinamide TDM using HPLC is valid and reliable. All the assay 
met the criteria involved in FDA and ICH. It means that this method can be applied in daily practice to understand 
the pharmacokinetic parameters of pyrazinamide which mostly related to the poor outcome of tuberculosis 
treatment. Previous study in tuberculosis patients with HIV infection showed that pyrazinamide peak concentration 
was low due to HIV infection [10]. Of the previous studies about TDM validation of antituberculosis, the HPLC-UV 
was the most valid and reliable instrument to do the TDM. 
One method which was used for pyrazinamide TDM was HPLC-diode array detector (HPLC-DAD) in two 
studies. The two studies showed that the method used in validation of rifampicin, isoniazide, ethambutol and 
pyrazinamide TDM in one pharmaceutical formulation met the requirement of linearity, precision and accuracy 
[11,12]. One of the method used mobile of monobasic sodium phosphate buffer with triethylamine and acetonitrile 
[12]. This method which is used in these previous studies was recommended due to its simplicity and accuracy [11]. 
The other method for pyrazinamide validation was in the formulation of ethionamide and pyrazinamide [13]. 
This study used reversed phase ion pair of HPLC for simultaneous detection of pyrazinamide and ethionamide and 
the mobile phase was trifluoroacetic acid in distilled water and acetonitrile:methanol. The concentration range of 
ethionamide and pyrazinamide was 0.1-3.0μg/mL and met the requirements for linearity, Accuracy, precision and 
specifity [13]. The difference of mobile phase component to our study is due to the lipophilic and hydrophilic 
character of the antituberculosis. Our study only tests pyrazinamid which is more hydrophilic than ethionamide, thus 
we only need to us acetonitrile:aquabidest as the mobile phase. This technique is selective for pyrazinamide, because 
there is no overlapping retention time with other medications. 
The previous study about TDM of antituberculosis is using electro spray tandem mass-spectrometry [14]. 
However, this method is quiet expensive to be applied in clinical setting in Indonesia.  Due to the limitation of 
sophisticated instruments in our country, the method using HPLC/UV is the most possible method which could be 
applied in the clinical settings. To understand the pharmacokinetic parameter of antituberculosis drugs during the 
treatment is important due to the high prevalence of tuberculosis and the incidence of multi-drug resistance and HIV 
infection in Indonesia.  
 
CONCLUSION 
We conclude that the method to do TDM of pyrazinamide using HPLC is valid and can be used in clinical 
setting. 
 
Concentration  
(μg/mL) 
Intraday  (n = 6) Interday (n = 6) 
Required Criteria* Mean ± SD 
(μg/mL) 
Precision 
(CV %) 
Accuracy 
(R %) 
Mean ± SD 
(μg/mL) 
Precision 
(CV %) 
Accuracy 
(R %) 
 
1 1,09± 0,01 1,17% 108,80% 1,03± 0,04 3,66% 103,18% Precision : 
 CV ≤ 15% 
 
Accuracy : 
80-120% 
8 7,41± 0,26 3,57% 92,57% 7,39± 0,10 1,37% 92,44% 
60 60,59 ± 2,01 3,32% 100,98% 56,96 ± 0,91 1,59% 94,94% 
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